DiaMedica Therapeutics
DMAC
32 hedge funds and large institutions have $12.7M invested in DiaMedica Therapeutics in 2024 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 7 closing their positions.
313% more call options, than puts
Call options by funds: $33K | Put options by funds: $8K
13% more capital invested
Capital invested by funds: $11.3M → $12.7M (+$1.48M)
1.67% more ownership
Funds ownership: 10.44% → 12.12% (+1.7%)
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
16% less funds holding
Funds holding: 38 → 32 (-6)
86% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Manhattan
New York
|
+$2.13M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$614K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$528K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$59.4K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$5.59K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Altium Capital Management
New York
|
-$817K |
| 2 |
Morgan Stanley
New York
|
-$437K |
| 3 |
Millennium Management
New York
|
-$81.9K |
| 4 |
AAS
Avantax Advisory Services
Dallas,
Texas
|
-$35.5K |
| 5 |
Bank of New York Mellon
New York
|
-$29.7K |
DMAC Hedge Fund Activity: Q1 2024 in Review
32 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in DiaMedica Therapeutics (DMAC) for Q1 2024, worth a combined $12.7M — up 13% from $11.3M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of DMAC and 1 opened new positions — a net loss of 6 holders — while 8 trimmed existing stakes and 7 added.
The largest buyer was First Manhattan, adding an estimated $2.13M. The largest seller was Altium Capital Management, exiting entirely with an estimated $817K sold.
- 32 institutional investors held DiaMedica Therapeutics (DMAC) as of Q1 2024, down from 38 in Q4 2023.
- Funds reported $12.7M of DiaMedica Therapeutics stock for Q1 2024, up 13% quarter-over-quarter.
- 1 fund opened new DiaMedica Therapeutics positions in Q1 2024 and 7 closed out, a net change of -6 holders.
- The largest DiaMedica Therapeutics buyer in Q1 2024 was First Manhattan, an estimated $2.13M added.
- The largest DiaMedica Therapeutics seller in Q1 2024 was Altium Capital Management, an estimated $817K sold.
Based on aggregated 13F filings for Q1 2024.